Publications by authors named "Christopher Catania"

Article Synopsis
  • The Intergovernmental Panel on Climate Change identifies increased carbon dioxide levels from human activities as the main cause of global climate change, emphasizing the need for technologies to reduce carbon footprints.
  • Carbon Capture Utilization and Storage (CCUS) technologies, including CO2-Enhanced processes and well rehabilitation methods like Aqua Freed and Aqua Gard, are recognized for their potential in sequestering carbon dioxide underground.
  • The study shows that these technologies can inject significant amounts of CO2 into wells, with an estimated 82-96% of that carbon remaining securely in the subsurface, indicating a substantial annual storage capacity in the US.
View Article and Find Full Text PDF

Patients diagnosed with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL) may achieve prolonged survival following receipt of high-dose chemotherapy/autologous stem cell transplantation (HDC/ASCT) or CD19-directed chimeric antigen receptor modified T cell therapy (CART19). Although early results from randomized clinical trials suggest that assignment to CART19 versus salvage immunochemotherapy as second-line therapy results in improved survival, analysis of a large series of patients who actually received HDC/ASCT or CART19 has yet to be performed. Such an analysis may inform future research efforts to optimize the risk stratification of R/R DLBCL/HGBL patients who are candidates for either therapy.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with refractory myeloid malignancies have a poor prognosis, and traditional allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning (MAC) has high relapse and mortality rates.
  • A new MAC regimen combining clofarabine and busulfan (Clo/Bu4) shows promise, especially for patients up to 70 years old, with a retrospective study identifying positive outcomes in a real-world setting.
  • Among 69 patients treated between 2012 and 2020, those with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) achieved notable event-free survival rates, with 72.5% in complete remission at day 100 post-transplant
View Article and Find Full Text PDF

Ratings surveillance is used in clinical trials to assure ratings reliability of site-based scores. One surveillance method employs audio-digital recordings of site-based clinician interviews to obtain remote, site-independent scores for assessment of paired scoring concordance and interview quality. We examined the utility of this surveillance strategy using paired site-independent scores derived from recorded site-based Montgomery-Asberg depression rating scale (MADRS) interviews obtained from patients with major depressive disorder (MDD) participating in 5 clinical trials.

View Article and Find Full Text PDF